Puheng Biomax Secures Tens of Millions in Funding to Advance NAC-Organ Platform for 3D In Vitro Disease Modeling and Drug Discovery
PDVC
Headquartered in Zhangjiang Hi-Tech Park and backed by the Yangtze River Delta economic circle, the company supports the development of small and medium-sized technology enterprises while achieving its own capital appreciation, thereby creating a win-win situation.
Recently, Puheng Biomai (Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as “Puheng Biomai,” formerly Suzhou Puheng Technology Co., Ltd.) completed a new round of financing, exclusively invested by the Pudong Sci-Tech Investment Angel Fund of Funds under Shanghai Pudong Venture Investment Co., Ltd. With this round, Puheng Biomai has raised tens of millions of yuan in cumulative financing. The proceeds will be primarily used for the continued development and commercial translation of its NAC-organ technology and in vitro drug R&D platform.
Puheng Bomai officially settled in Pudong New Area, Shanghai, in December 2023. It is an innovative enterprise dedicated to the research, development, and application of novel ex vivo 3D organ/disease models.The company’s independently developed NAC-Organ technology is the world’s first assembly-based in vitro 3D organ/disease model construction and culture technology based on nano-nucleic acid materials. It enables rapid, high-throughput, and standardized production of humanized complex organ/disease models, addressing industry pain points such as the low clinical relevance of preclinical drug evaluation models and the difficulties in scaling up and standardizing the production of in vitro 3D organ/disease models, thereby providing a more efficient and precise technical platform for new drug development.
The company has established modeling technologies featuring chronic liver diseases, encompassing common chronic conditions, various tumors, vital physiological organs, and multi-organ complex models. It has built a comprehensive testing platform and multidimensional evaluation system integrating image analysis, immunohistochemistry, molecular biology, pathology, and AI-based predictions, thereby facilitating the research and development of diverse therapeutic modalities, including small molecules, biologics, cell therapies, and nucleic acid drugs. Currently, the drug R&D services provided by Puheng Bomai have garnered high recognition from numerous renowned pharmaceutical companies both in China and abroad.
Puheng Bomi will continue to invest in the development of new products based on NAC-organ technology, constantly build and improve automated, high-throughput drug testing platforms and evaluation systems, strive to shorten the drug development cycle, and provide systematic solutions for new drug research and development.
Dr. Song Guangqi, Founder of Puheng BomaiStatement: We extend our gratitude to the Pudong Angel Fund of Funds for its recognition of Puheng Bomed, and also thank Guoqian Venture Capital, our angel investor, for its continued trust and support. At present, global new drug R&D continues to grow steadily. In vitro 3D model technology has gained widespread acceptance from numerous pharmaceutical companies and regulatory agencies, emerging as a highly anticipated new tool in drug development. Puheng Bomed will seize this market opportunity by accelerating technological R&D and product portfolio deployment. Leveraging the core advantages of its NAC-organ technology, the company will rapidly expand its presence in the markets for new drug R&D services, medical research services, and precision medicine.
Pudong Technology Investment Angel Fund of FundsIt is stated that, through this investment, the Pudong Science and Technology Investment Angel Fund of Funds has attracted PuHeng BoMai to settle in the Pudong New Area. This move will facilitate the continuous development and commercial translation of the company’s NAC-organ technology and in vitro drug platforms, accelerate its comprehensive layout in preclinical drug research, medical research, and precision medicine services, and provide systematic solutions to address the long cycles, high risks, and substantial costs inherent in new drug R&D. Furthermore, it will foster synergistic development across the upstream and downstream segments of Pudong’s biopharmaceutical industry chain and enhance the industrial ecosystem.